About 1 in 9 Americans over 65 suffers from Alzheimer’s. It is the sixth leading cause of death and the most expensive disease in the United States, and there is no cure. This year, the disease is expected to carry a $345 billion price tag, according to the Alzheimer’s Association.   
 
Unfortunately, treatment options are still limited. However, earlier this year, the U.S. Food and Drug Administration granted accelerated approval for the drug Leqembi, but due to the controversial approval of another drug, Aduhelm, in 2021 based on mixed evidence of its efficacy, the Centers for Medicare and Medicaid have declined to cover these new drugs under most circumstances.  
 
Why is CMS declining coverage, and where are we in terms of new treatments on the horizon? And what can be done to address disparities and ensure all communities receive needed care? 
 
The Hill will bring together lawmakers, researchers, doctors, caregivers, and patients to explore the latest treatments and roadblocks and investigate what more needs to be done to curb this disease.